Novo Nordisk A/S

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann J, Persson F, Pratley RE, et al. Journal article Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER (2019) Perkovic V, Bain SC, Bakris G, Buse JB, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials (2019) Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, et al. Conference contribution EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial" (2019) Mann J, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Journal article, Note Health-related quality of life in people with type 2 diabetes participating in the LEADER trial (2019) Nauck MA, Buse JB, Mann J, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A Journal article Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events (2018) Husain M, Bain SC, Mann J, Nauck M, Poulter N, Baeres FMM, Goldman B, et al. Conference contribution Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck MA, Nissen SE, et al. Journal article